Bookmark and Share

News Article

UK drug pricing must reward innovation
The Association of the British Pharmaceutical Industry has called for the UK’s future pricing system to reflect incremental medical innovation rather than prizing headline medical advances above all else. To date the focus has been on the anticipated introduction of VBP, which is likely to allow companies to sell drugs at higher prices based on a series of cost-effectiveness thresholds. However, many in the industry are worried that the changes would create a system that does not offer sufficient reward for more incremental drug developments. (Source: PMLiVE, 6/7/12)

Read more.
Bookmark and Share